Our published data and the preliminary data presented in this application have demonstrated that hyperglycemia suppresses AMPK, which in turn perpetuates oxidative stress and vascular injury in diabetes. The central hypothesis of this application is that AMPK12 inhibition increases 26S activity, which increases I:B1 degradation, p65 nucleus localization, and consequent NF:B activation. Activated NF:B binds to the promoter of NAD(P)H oxidase subunits, including NOX4, gp91phox(NOX2), p67phox, p47phox, resulting in an increase in NAD(P)H oxidase activity and ROS, which causes endothelial cell dysfunction and accelerated atherosclerosis. Chronic proteasome inhibition of the 26S proteasome prevents endothelial dysfunction and atherogenesis by inhibiting proteasome-dependent NF:B-mediated activation of NAD(P)H oxidase. This hypothesis will be tested in three interrelated aims. These first two aims are designed to establish whether chronic hyperglycemia inhibition AMPK functions (Aim #1) and whether AMPK inhibition causes abnormal expression of adhesion molecules and oxidant stress in diabetes (Aim #2). Finally, we will test the contributions of RNS-mediated AMPK inhibition in the development of accelerated atherosclerosis in diabetes (Aim #3). Although the in vivo relationships among atherosclerosis, oxidant stress, and AMPK in diabetes are undoubtedly complex, the emerging role for AMPK in oxidant stress and atherosclerosis warrant further study. The studies proposed here represent the first set of definitive studies to determine the role of ONOO- and AMPK inhibition in the pathogenesis of diabetic vascular dysfunction and atherosclerosis. As such, they have the potential to explain the long recognized decrease in AMPK that occurs in animals and human patients with diabetes. We believe that the proposed studies will provide novel information as to how the metabolic stress associated with diabetes causes damage to the endothelium and how the endothelial cell attempts to protect itself against these stresses and whether ONOO- or AMPK are potential targets for therapy.
Recent studies from the applicant's group and others support the idea that oxidant stress is a common pathogenic mechanism for cardiovascular diseases including diabetes, hypertension, and atherosclerosis. But the mechanisms are poorly defined. Thus, this application is aimed to determine 1) how diabetes inhibits AMPK in endothelial cells;2) To determine how AMPK inhibition results in excessive inflammation and oxidant stress;and 3) to determine the contribution of AMPK inhibition in diabetes-enhanced atherosclerosis in mouse models of atherosclerosis in vivo.
|Yu, Xi-Yong; Song, Ping; Zou, Ming-Hui (2018) Obesity Paradox and Smoking Gun: A Mystery of Statistical Confounding? Circ Res 122:1642-1644|
|Wang, Bei; Nie, Jiali; Wu, Lujin et al. (2018) AMPK?2 Protects Against the Development of Heart Failure by Enhancing Mitophagy via PINK1 Phosphorylation. Circ Res 122:712-729|
|Lu, Qiulun; Xie, Zhonglin; Yan, Chenghui et al. (2018) SNRK (Sucrose Nonfermenting 1-Related Kinase) Promotes Angiogenesis In Vivo. Arterioscler Thromb Vasc Biol 38:373-385|
|Han, Young-Min; Bedarida, Tatiana; Ding, Ye et al. (2018) ?-Hydroxybutyrate Prevents Vascular Senescence through hnRNP A1-Mediated Upregulation of Oct4. Mol Cell 71:1064-1078.e5|
|Wang, Qiongxin; Ding, Ye; Song, Ping et al. (2017) Tryptophan-Derived 3-Hydroxyanthranilic Acid Contributes to Angiotensin II-Induced Abdominal Aortic Aneurysm Formation in Mice In Vivo. Circulation 136:2271-2283|
|Liu, Zhaoyu; Zhu, Huaiping; Dai, Xiaoyan et al. (2017) Macrophage Liver Kinase B1 Inhibits Foam Cell Formation and Atherosclerosis. Circ Res 121:1047-1057|
|Okon, Imoh; Ding, Ye; Zou, Ming-Hui (2017) Ablation of Interferon Regulatory Factor 3 Promotes the Stability of Atherosclerotic Plaques. Hypertension 69:407-408|
|Song, Ping; Ramprasath, Tharmarajan; Wang, Huan et al. (2017) Abnormal kynurenine pathway of tryptophan catabolism in cardiovascular diseases. Cell Mol Life Sci 74:2899-2916|
|Zhang, W; Ding, Y; Zhang, C et al. (2017) Deletion of endothelial cell-specific liver kinase B1 increases angiogenesis and tumor growth via vascular endothelial growth factor. Oncogene 36:4277-4287|
|Ding, Ye; Zou, Ming-Hui (2017) AMP-Activated Protein Kinase ?2 to the Rescue in Ischemic Heart. Circ Res 121:1113-1115|
Showing the most recent 10 out of 93 publications